Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Hirokuni Ikeda"'
Autor:
Hirokuni Ikeda, Shinichi Toyooka, Junji Matsuoka, Hiroyoshi Doihara, Yuko Takahashi, Mariko Kochi, Yukiko Kajiwara, Naruto Taira, Yoko Suzuki, Minami Hatono, Takahiro Tsukioki, Takayuki Iwamoto, Kengo Kawada, Tadahiko Shien
Publikováno v:
Clinical Breast Cancer. 20(2):117-124
Introduction Patients with residual disease usually have a poor prognosis after neoadjuvant chemotherapy for breast cancer. The aim of this study was to explore therapeutic targets and potential additional adjuvant treatments for patients with residu
Autor:
Mariko Kochi, Miwa Fujihara, Tadahiko Shien, Takahiro Tsukioki, Yukiko Kajiwara, Hiroyoshi Doihara, Hirokuni Ikeda, Takayuki Iwamoto, Naruto Taira, Kengo Kawada, Yoko Suzuki, Minami Hatono, Yusuke Otani
Publikováno v:
Cancer Research. 80:P5-13
Background In hormone receptor (HR)-positive / human epidermal growth factor receptor 2 (HER2)-negative breast cancers, high Ki-67 predicts poor prognosis. Recently, it has been reported that among breast cancers with high Ki-67, low Ki-67 after shor
Autor:
Hirokuni Ikeda, Yuichiro Kikawa, Yoko Suzuki, Hiroyoshi Doihara, Takayuki Iwamoto, Mariko Kochi, Tadahiko Shien, Naruto Taira, Yukiko Kajiwara, Yukari Uemura
Publikováno v:
Cancer Research. 80:OT3-19
Background: Patient reported outcomes (PROs) have been increasingly important in breast cancer treatment. The questionnaires to evaluate PROs require high response compliance, simplicity, and friendliness. Recently, the communication with Emojis has
Autor:
Kentaro Sakamaki, Hiroyoshi Doihara, Yuko Takahashi, Kohei Kawata, Hirokuni Ikeda, Yukiko Kajiwara, Takayuki Iwamoto, Tadahiko Shien, Naruto Taira, Takahiro Tsukioki, Yoko Suzuki, Minami Hatono, Mariko Kochi
Publikováno v:
Cancer Research. 79:P4-08
Background: Overall survival (OS) is the established endpoint to evaluate the effects of drug treatment in comparative clinical trials of metastatic breast cancer. But assessing OS requires long follow-up periods and large sample size, which raise co
Autor:
Hirokuni Ikeda, Mariko Kochi, Tadahiko Shien, Yuko Takahashi, Yoko Suzuki, Minami Hatono, Naruto Taira, Takayuki Iwamoto, Yukiko Kajiwara, Kohei Kawata, Takahiro Tsukioki, Hiroyoshi Doihara
Publikováno v:
Cancer Research. 79:P2-05
Background : Isoflavones are phytoestrogens that may be effective in preventing osteoporosis, reducing cardiovascular events, and improving menopausal symptoms such as hot flash due to their estrogen-like actions. Isoflavones are currently used as a
Autor:
Tadahiko Shien, Yuta Takahashi, Junichi Soh, Minami Hatono, Shinichi Toyooka, Hiromasa Yamamoto, Yusuke Ogoshi, Hidejiro Torigoe, Takahiro Yoshioka, Shuta Tomida, Kei Namba, Eisuke Kurihara, Hirokuni Ikeda, Masakiyo Sakaguchi, Hiroki Sato, Kazuhiko Shien
Publikováno v:
Cancer Science
Compensatory activation of the signal transduction pathways is one of the major obstacles for the targeted therapy of non‐small cell lung cancer (NSCLC). Herein, we present the therapeutic strategy of combined targeted therapy against the MEK and p
Autor:
Hiroyoshi Doihara, Tadahiko Shien, Yoko Suzuki, Takayuki Iwamoto, Minami Hatono, Takehiro Tanaka, Yukiko Kajihara, Mariko Kochi, Naruto Taira, Kengo Kawada, Takahiro Tsukioki, Hirokuni Ikeda, Shinichi Toyooka
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Metformin has been suggested to possibly reduce cancer risk. However, the mechanism underlying the positive effects of metformin on cancer treatment remains unclear. We conducted a prospective study to evaluate the effects of preoperative met
Effect of isoflavones on breast cancer cell development and their impact on breast cancer treatments
Autor:
Hiromasa Yamamoto, Mariko Kochi, Takahiro Tsukioki, Yukiko Kajiwara, Tadahiko Shien, Masaomi Yamane, Yoko Suzuki, Takayuki Iwamoto, Minami Hatono, Kengo Kawada, Hirokuni Ikeda, Shinichi Toyooka, Ken Suzawa, Naruto Taira, Hiroyoshi Doihara
Publikováno v:
Breast cancer research and treatment. 185(2)
Epidemiological studies have suggested that intake of soy isoflavones is associated with a reduced risk of development of breast cancer and an improved prognosis in patients with breast cancer. In addition, basic research has demonstrated the antitum
Autor:
Hirokuni Ikeda, Hiroyoshi Doihara, Shozo Ohsumi, Tadahiko Shien, Reiki Nishimura, H. Masuda, Naruto Taira, Tomohiro Nogami, Daisuke Takabatake
Publikováno v:
Cancer Research. 70:P5-14
Background: The treatment for metastatic breast cancer (MBC) is usually systemic therapy decided by the hormone and HER2 status of primary breast cancer lesion. There are some reports about the discrepancy in hormone and HER2 status between primary a
Autor:
Hirokuni Ikeda, Tomohiro Nogami, Tadahiko Shien, Masanori Okada, Naruto Taira, Kazuhiko Shien, Shinichiro Miyoshi, Hiroyoshi Doihara
Publikováno v:
Cancer science. 102(11)
Patients with estrogen receptor (ER)-positive breast cancers have a better prognosis than those with ER-negative breast cancers, but often have low sensitivity to chemotherapy and a limited survival benefit. We have previously shown a combination eff